News Novartis Pharma

Novartis Accuses Avexis Ex-Employees of Data Manipulation in Development of Zolgensma

Biotech News | 25.09.2019

According to Novartis, two former high-ranking employees of the subsidiary Avexis are responsible...

News Novartis Pharma

Novartis Presents Interim Analysis of its Phase 3 trial of Zolgensma in Spinal Muscular Atrophy Type 1

Biotech News | 19.09.2019

The gene therapy player AveXis which was acquired by Novartis for $8.7 billion in 2018 today...

News Novartis Pharma

Novartis Paves the Way Towards a Fourth Indication for Cosentyx: Positive Phase 3 Trial Data in Non-Radiographic Spondyloarthritis

Biotech News | 18.09.2019

The Swiss pharma giant Novartis today announced new data from its phase 3 clinical trial program...

News Novartis Pharma

Novartis Presents Phase 3 Data of its Clinical Trials ASCLEPIOS I and II with Arzerra (Ofatumumab) in Patients with Relapsing Multiple Sclerosis

Biotech News | 14.09.2019

Novartis makes major progress towards the anticipated approval for its multiple sclerosis (MS) drug...

News Novartis Pharma

Novartis Holds on to Sandoz Generics Subsidiary

Biotech News | 27.07.2019

Novartis CEO ends speculation about sale of Sandoz and Hexal Genrika divisions. The aim is to make...